Effect of amphetamine on extracellular concentrations of amino acids in striatum in neurotensin subtype 1 and 2 receptor null mice: A possible interaction between neurotensin receptors and amino acid systems for study of schizophrenia

Neuropharmacology

Volumn 58, Issue 7, 2010, Pages 1174-1178

  Li, Zhimin ^a   Liang, Yanqi ^a   Boules, Mona ^a   Gordillo, Andres ^a   Richelson, Elliott ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; AMPHETAMINE; ASPARTIC ACID; GLUTAMIC ACID; GLYCINE; NEUROTENSIN; NEUROTENSIN 1; NEUROTENSIN 2; SERINE; UNCLASSIFIED DRUG;

4 AMINOBUTYRIC ACID RELEASE; AMINO ACID BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFICACY; GABAERGIC TRANSMISSION; GENE FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA;

AMINO ACIDS; AMPHETAMINE; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; CORPUS STRIATUM; EXTRACELLULAR SPACE; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, NEUROLOGICAL; RECEPTORS, NEUROTENSIN; SCHIZOPHRENIA; SERINE;

EID: 77950949711     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.02.016     Document Type: Article

References (39)

1. Antonelli T., Fuxe K., Tomasini M.C., Mazzoni E., Agnati L.F., Tanganelli S., Ferraro L. Neurotensin receptor mechanisms and its modulation of glutamate transmission in the brain: relevance for neurodegenerative diseases and their treatment. Prog. Neurobiol. 2007, 83:92-109.
2. Binder E.B., Kinkead B., Owens M.J., Kilts C.D., Nemeroff C.B. Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: evidence from animal models of sensorimotor gating. J. Neurosci. 2001, 21:601-608.
3. Boules M., Liang Y., Briody S., Miura T., Fauq I., Oliveros A., Wilson M., Khaniyev S., Williams K., Li Z., Qi Y., Katovich M., Richelson E. NT79: a novel neurotensin analog with selective behavioral effects. Brain Res. 2010, 1308:35-46.
4. Breslin N.A., Suddath R.L., Bissette G., Nemeroff C.B., Lowrimore P., Weinberger D.R. CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates. Schizophr Res. 1994, 12:35-41.
5. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., Carlsson M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu. Rev. Pharmacol. Toxicol. 2001, 41:237-260.
6. Del Arco A., Castaneda T.R., Mora F. Amphetamine releases GABA in striatum of the freely moving rat: involvement of calcium and high affinity transporter mechanisms. Neuropharmacology 1998, 37:199-205.
7. Del Arco A., González-Mora J.L., Armas V.R., Mora F. Amphetamine increases the extracellular concentration of glutamate in striatum of the awake rat: involvement of high affinity transporter mechanisms. Neuropharmacology 1999, 38:943-954.
8. Exposito I., Del Arco A., Segovia G., Mora F. Endogenous dopamine increases extracellular concentrations of glutamate and GABA in striatum of the freely moving rat: involvement of D1 and D2 dopamine receptors. Neurochem. Res. 1999, 24:849-856.
9. Feifel D., Pang Z., Shilling P.D., Melendez G., Schreiber R., Button D. Sensorimotor gating in neurotensin-1 receptor null mice. Neuropharmacology 2010, 58:173-178.
10. Ferraro L., Tomasini M.C., Mazza R., Fuxe K., Fournier J., Tanganelli S., Antonelli T. Neurotensin receptors as modulators of glutamatergic transmission. Brain Res. Rev. 2008, 58:365-373.
11. Garver D.L., Bissette G., Yao J.K., Nemeroff C.B. Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients. Am. J. Psychiatry 1991, 148:484-488.
12. Gray A.M., Rawls S.M., Shippenberg T.S., McGinty J.F. The kappa-opioid agonist, U-69593, decreases acute amphetamine-evoked behaviors and calcium-dependent dialysate levels of dopamine and glutamate in the ventral striatum. J. Neurochem. 1999, 73:1066-1074.
13. Hashimoto K., Fukushima T., Shimizu E., Komatsu N., Watanabe H., Shinoda N., Nakazato M., Kumakiri C., Okada S., Hasegawa H., Imai K., Iyo M. Decreased serum levels of d-serine in patients with schizophrenia: evidence in support of the N-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia. Arch. Gen. Psychiatry 2003, 60:572-576.
14. Heresco-Levy U., Javitt D.C., Ebstein R., Vass A., Lichtenberg P., Bar G., Catinari S., Ermilov M. d-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol. Psychiatry 2005, 57:577-585.
15. Kim J.S., Kornhuber H.H., Schmid-Burgk W., Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 1980, 20:379-382.
16. Kim E.R., Leckstrom A., Mizuno T.M. Impaired anorectic effect of leptin in neurotensin receptor 1-deficient mice. Behav. Brain Res. 2008, 194:66-71.
17. Kinkead B., Binder E.B., Nemeroff C.B. Does neurotensin mediate the effects of antipsychotic drugs?. Biol. Psychiatry 1999, 46:340-351.
18. Kinkead B., Dobner P.R., Egnatashvili V., Murray T., Deitemeyer N., Nemeroff C.B. Neurotensin-deficient mice have deficits in prepulse inhibition: restoration by clozapine but not haloperidol, olanzapine, or quetiapine. J. Pharmacol. Exp. Ther. 2005, 315:256-264.
19. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51:199-214.
20. Lahti A.C., Holcomb H.H., Medoff D.R., Tamminga C.A. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 1995, 6:869-872.
21. Laruelle M., Kegeles L.S., Abi-Dargham A. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann. N. Y. Acad. Sci. 2003, 1003:138-158.
22. Laruelle M., Frankle W.G., Narendran R., Kegeles L.S., Abi-Dargham A. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation. Clin. Ther. 2005, 27(Suppl. A):S16-S24.
23. Leonetti M., Brun P., Clerget M., Steinberg R., Soubrie P., Renaud B., Suaud-Chagny M.F. Specific involvement of neurotensin type 1 receptor in the neurotensin-mediated in vivo dopamine efflux using knock-out mice. J. Neurochem. 2004, 89:1-6.
24. Lyon G.J., Abi-Dargham A., Moore H., Lieberman J.A., Javitch J.A., Sulzer D. Presynaptic regulation of dopamine transmission in schizophrenia. Schizophr. Bull. 2009, (Epub ahead of print).
25. Mazella J., Botto J.M., Guillemare E., Coppola T., Sarret P., Vincent J.P. Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain. J. Neurosci. 1996, 16:5613-5620.
26. Mazella J., Zsurger N., Navarro V., Chabry J., Kaghad M., Caput D., Ferrara P., Vita N., Gully D., Maffrand J.P., Vincent J.P. The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor. J. Biol. Chem. 1998, 273:26273-26276.
27. Mechanic J.A., Sutton J.E., Berson A.E., Wu X., Kwan J., Schreiber R., Pang Z., Button D.C. Involvement of the neurotensin receptor 1 in the behavioral effects of two neurotensin agonists, NT-2 and NT69L: lack of hypothermic, antinociceptive and antipsychotic actions in receptor knockout mice. Eur. Neuropsychopharmacol. 2009, 19:466-475.
28. Miele M., Mura M.A., Enrico P., Esposito G., Serra P.A., Migheli R., Zangani D., Miele E., Desole M.S. On the mechanism of d-amphetamine-induced changes in glutamate, ascorbic acid and uric acid release in the striatum of freely moving rats. Br. J. Pharmacol. 2000, 129:582-588.
29. Mo Y.Q., Jin X.L., Chen Y.T., Jin G.Z., Shi W.X. Effects of l-stepholidine on forebrain Fos expression: comparison with clozapine and haloperidol. Neuropsychopharmacology 2005, 30:261-267.
30. Nemeroff C.B. Neurotensin: perchance an endogenous neuroleptic?. Biol. Psychiatry 1980, 15:283-302.
31. Paxinos G., Franklin K.B.J. The Rat Brain in Stereotaxic Coordinates 2001, Academic Press, Sydney.
32. Pettibone D.J., Hess J.F., Hey P.J., Jacobson M.A., Leviten M., Lis E.V., Mallorga P.J., Pascarella D.M., Snyder M.A., Williams J.B., Zeng Z. The effects of deleting the mouse neurotensin receptor NTR1 on central and peripheral responses to neurotensin. J. Pharmacol. Exp. Ther. 2002, 300:305-313.
33. Porras A., Mora F. Dopamine receptor antagonist blocks the release of glycine, GABA, and taurine produced by amphetamine. Brain Res. Bull. 1993, 31:305-310.
34. Sharma R.P., Janicak P.G., Bissette G., Nemeroff C.B. CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder. Am. J. Psychiatry 1997, 154:1019-1021.
35. van Berckel B.N., Kegeles L.S., Waterhouse R., Guo N., Hwang D.R., Huang Y., Narendran R., Van Heertum R., Laruelle M. Modulation of amphetamine-induced dopamine release by group II metabotropic glutamate receptor agonist LY354740 in non-human primates studied with positron emission tomography. Neuropsychopharmacology 2006, 31:967-977.
36. Vita N., Laurent P., Lefort S., Chalon P., Dumont X., Kaghad M., Gully D., Le Fur G., Ferrara P., Caput D. Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor. FEBS Lett. 1993, 317:139-142.
37. Yamamoto B.K., Davy S. Dopaminergic modulation of glutamate release in striatum as measured by microdialysis. J. Neurochem. 1992, 58:1736-1742.
38. Yamauchi R., Wada E., Kamichi S., Yamada D., Maeno H., Delawary M., Nakazawa T., Yamamoto T., Wada K. Neurotensin type 2 receptor is involved in fear memory in mice. J. Neurochem. 2007, 102:1669-1676.
39. Zhao S., Yuan H., Xiao D. Detection of d-Serine in rat brain by capillary electrophoresis with laser induced fluorescence detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2005, 822:334-338.